NEJM: Egle Net does not increase cardiovascular risk in people with type 2 diabetes with atherosclerosis cardiovascular disease.

Researchers recently assessed the effects of SGLT-2 inhibitor Ertugliflozin on cardiovascular risk in people with type 2 diabetes.
in this multi-center, double-blind trial, patients with type 2 diabetes with atherosclerotic cardiovascular disease were recruited to receive 5 mg, 15 mg of Eglis or placebo at random once a day.
of the study were cardiovascular adverse events, including cardiovascular disease deaths, non-fatal myocardial infarction, or non-fatal stroke deaths, with secondary results being cardiovascular disease deaths or hospitalization for heart failure.
8,246 patients participated in the study, with an average follow-up of 3.5 years, of which 8,238 had received at least one Eglis or placebo treatment, 653 (11.9%) out of 5,493 patients in the Egle net group, and 327 (11.9%) of the 2,745 patients in the placebo group had major cardiovascular adverse events (risk ratio 0.97).
Of the 5,499 patients in the Egle net group, 444 (8.1%) died of cardiovascular disease or were hospitalized for heart failure, compared with 250 (9.1% with a risk ratio of 0.88) out of 2,747 patients in the placebo group.
risk of death from cardiovascular causes was 0.92 for patients after Eglia's net treatment, and 0.81 for kidney-caused death, kidney replacement therapy or double serum creatinine levels.
54 (2.0 per cent) received 5mg EGLE net treatment and 57 (2.1 per cent) patients (2.1 per cent) received 15mg Egli net treatment, compared with 45 placebo patients (1.6 per cent).
study found that for people with type 2 diabetes with atherosclerotic cardiovascular disease, the risk of cardiovascular adverse events after Egle net treatment was comparable to that of placebo.
.